Insiders who reported open-market trades in the last 12 months at the companies Jacqueline Zummo files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jesse Shefferman - $882K in TARA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Jacqueline Zummo is a corporate insider, tracked as Chief R&D Officer of Protara Therapeutics, Inc. (TARA). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Jacqueline Zummo last file a Form 4?
The most recent primary Form 4 on record is dated 9 April 2026, one of 5 filings going back to 2026.
Has Jacqueline Zummo been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($125K) across all tracked filings.
Jacqueline Zummo is Chief R&D Officer of Protara Therapeutics, Inc. (TARA). 5 SEC Form 4 filings on record, most recently on 9 April 2026. Most recent open-market trade: sold $6K of TARA on 9 April 2026. Lifetime open-market sales: $125K.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by Jacqueline Zummo.
InsiderAlpha's records for Jacqueline Zummo go back to 2026: 5 primary Form 4 filings, an average of 5.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
